Search results
Results from the WOW.Com Content Network
MRI contrast agents may be administered by injection into the blood stream or orally, depending on the subject of interest. Oral administration is well suited to gastrointestinal tract scans, while intravascular administration proves more useful for most other scans. MRI contrast agents can be classified [2] by their: Chemical composition
Gadopentetic acid, sold under the brand name Magnevist, is a gadolinium-based MRI contrast agent. [2]It is usually administered as a salt of a complex of gadolinium with DTPA (diethylenetriaminepentacetate) with the chemical formula A 2 [Gd(DTPA)(H 2 O)]; when cation A is the protonated form of the amino sugar meglumine the salt goes under the name "gadopentetate dimeglumine".
It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd 3+), and is used in form of the meglumine salt (gadoterate meglumine). [4] [5] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because ...
Gadoxetic acid is a gadolinium-based MRI contrast agent. [4] Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals. [2] [5]
Gadodiamide is a contrast medium used for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. It provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS).
Gadopiclenol, sold under the brand name Elucirem among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. [2] [7] Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium. [2]
Pediatric patients, scheduled for a routine contrast-enhanced MRI examination of any body region, both male and female, under the age of 2 years old could be enrolled in the study. The open-label, multi-center, pharmacokinetic and safety test studied the way gadobutrol was taken into, moved around, and was eliminated from the body of the infants.
Appropriate use criteria by the American College of Radiology give a rating of ≥7 (usually appropriate) for non-contrast MRI for the following conditions: Acute non-localized pain in the right upper quadrant or right lower quadrant (in concurrent fever and leukocytosis) [3] Acute pelvic pain when a non-gynecological cause is suspected [3]